We also evaluated the association between KDM5C expression and several inhibitory (e.g., CD160, CD96, CSF1R, CTLA-4, TIM-3, IDO1, IL10, LAG3, PD-1, PD-L1, PD-L2, TFGB1, TGFBR1, TIGIT, VEGFA) and stimulatory (e.g., CD27, CD28, CD40, CD40LG, CD70, CD80, CD86, CXCL12, CXCR4, ICOS, ICOSLG, MICA, MICB, TNFRSF14, TNFRSF17, TNFRSF18, TNFRSF4, TNFRSF9, TNFSF9, TNFSF13) immune checkpoints expression in various cancers. The gene discussed is CD160; the disease is cancer.